Latest News

It’s been building for quite a while, but the dam seems to be breaking, and the 2 themes seem to be transparency and fiduciary duty.

OTC naloxone nasal sprays expand overdose rescue; pharmacists guide proper use, tackle stigma, and help communities curb opioid deaths.

A large observational study identifies U-shaped relationship between weekday sleep duration and estimated glucose disposal rate.

Ipsen discontinues tazemetostat after SYMPHONY-1 safety signals; pharmacists and FDA guide next steps for EZH2-mutant follicular lymphoma patients.

Adherence to glucose-lowering drugs ranges from 41% to 68% depending on drug class.

Early detection and prevention reduce risks of diverse adverse drug reactions.

Look‑alike, soundalike drugs increase errors, but systems can prevent them.

The FDA approves Bristol Myers Squibb’s deucravacitinib (Sotyktu), a first oral tyrosine kinase 2 inhibitor for active psoriatic arthritis.

Pharmacists quietly prevent medication harm, ease discharge chaos, and manage rising health care strain through unseen cognitive work.

Peptide compounders face rising scrutiny as regulators and lawsuits lean on USP <795> and <797>.

As the spring travel season approaches, more than 30 countries appear on the CDC's circulating polio alert list.

New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.

Health systems coordinate pharmacy, payers, clinicians, labs, and electronic health record (EHR) teams to deliver ultra-high-cost gene therapies.

Pembrolizumab neoadjuvant immunotherapy hits approximately 70% complete responses in desmoplastic melanoma.

Phase 4 data show suzetrigine controls post–plastic surgery pain, keeping nearly 91% of patients opioid free with good pain ratings and tolerability.

A Baptist Health pharmacy expert shares real-world myelofibrosis oncology tips on JAK selection, symptom control, and navigating specialty drug costs.

FDA approval expands teclistamab plus daratumumab significantly improved survival in the MajesTEC-3 trial.

Meta-analysis finds insulin efsitora provides similar glycemic control with superior hemoglobin A1C reduction at 52 weeks and lower total weekly insulin dose, while maintaining an acceptable safety profile.

A single intranasal formulation demonstrated protection against SARS-CoV-2, bacterial pneumonia, and allergens for up to 3 months in preclinical models.

Tanika Kelly, PhD, MPH, discusses her study finding that greater chronic kidney disease (CKD) severity significantly increases the risk of cognitive impairment, with important implications for how pharmacists counsel and support these patients.